ROCK Inhibition: An exploration of a new way to manage Glaucoma

Join our panel of expert speakers, chaired by Professor Rupert Bourne (Cambridge University Hospital) to explore the newest innovation in glaucoma medicine.

Presentations will include The function and dysfunction of the trabecular meshwork in glaucoma by Dr Andrew Tatham (Princess Alexandra Eye Pavilion), Visualising the trabecular meshwork by Dr Carl Sheridan (University of Liverpool) and ROCLANDA®▼: Challenging convention in medical management of glaucoma by Dr Karl Mercieca (University Eye Clinic, Bonn).

UK Abbreviated Prescribing Information can be found here.

Irish Abbreviated Prescribing Information can be found here.

Adverse events should be reported. Reporting forms and information for UK can be found at https://yellowcard.mhra.gov.uk/. Adverse events should also be reported to Santen UK Limited (Email: medinfo@santen.co.uk or telephone: 0345 075 4863). Reporting forms and information for Ireland can be found at www.hpra.ie and adverse events should be reported to telephone: +353 1 695 0008.

ROCLANDA® (50μg/mL latanoprost + 200μg/mL netarsudil) is indicated for the reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction.